Edition:
United States

People: OPKO Health Inc (OPK.O)

OPK.O on Nasdaq

2.10USD
16 Jul 2019
Change (% chg)

$0.00 (+0.00%)
Prev Close
$2.10
Open
$2.16
Day's High
$2.18
Day's Low
$2.10
Volume
2,806,320
Avg. Vol
4,624,779
52-wk High
$6.40
52-wk Low
$1.73

Logal, Adam 

Mr. Adam E. Logal serves as Senior Vice President, Chief Financial Officer of the Company. Mr. Logal has served as OPKO’s Senior Vice President and Chief Financial Officer since March 2014, Vice President of Finance, Chief Accounting Officer and Treasurer from July 2012 until March 2014, and Director of Finance, Chief Accounting Officer and Treasurer from March 2007 until July 2012. He currently serves as chairman of the board of directors of Xenetics Biosciences, Inc. (NASDAQ CM:XBIO), a clinical-stage biopharmaceutical company focused on discovery, research and development of next-generation biologic drugs and novel orphan oncology therapeutics. He previously served on the board of directors of VBI Vaccines, Inc. (NASDAQ:VBIV) until 2018. From 2002 to 2007, Mr. Logal served in senior management of Nabi Biopharmaceuticals, a publicly traded, biopharmaceutical company engaged in the development and commercialization of proprietary products. Mr. Logal held various positions of increasing responsibility at Nabi Biopharmaceuticals, last serving as Senior Director of Accounting and Reporting.

Basic Compensation

Total Annual Compensation, USD 600,000
Restricted Stock Awards, USD --
Long-Term Incentive Plans, USD --
All Other, USD 650,000
Fiscal Year Total, USD 1,250,000

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised 11,054 62,250.00
Name Fiscal Year Total

Phillip Frost

2,036,000

Geoff Monk

--

Jane Hsiao

1,976,000

Adam Logal

1,250,000

Jon Cohen

--

Steven Rubin

1,460,000
As Of  30 Dec 2018